Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $19.55 (174.13% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetActions
6/27/2016Robert W. BairdInitiated CoverageOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016WedbushReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Jefferies GroupDowngradeBuy -> Hold$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Raymond James Financial Inc.Initiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Bank of America Corp.DowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.74)($0.75)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.82)($0.81)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.87)($0.85)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.77)($0.92)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.75)($0.74)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.66)($0.79)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.52)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.50)($1.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.47)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.79)($0.73)($0.75)
Q2 20163($0.76)($0.73)($0.74)
Q3 20163($0.75)($0.75)($0.75)
Q4 20163($0.76)($0.75)($0.76)
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.55)($0.55)($0.55)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
DateHeadline
07/24/16 09:10 AMIs $20 Price Target Attainable For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Investor Newswire
07/21/16 11:01 AMKaryopharm Therapeutics Inc. (KPTI) Drops 6.82% on July 19 - Equities.com
07/20/16 07:51 AMWhat Next for Karyopharm Therapeutics Inc Stock After Today's Huge Decline? - Consumer Eagle
07/20/16 07:51 AMKaryopharm Therapeutics Inc. (NASDAQ:KPTI): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 10:10 AMTrading Performance and Target Watch for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Press Telegraph
07/16/16 04:33 PMStrong Sell Calls For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 0 - Investor Newswire
07/16/16 04:33 PMKaryopharm Therapeutics Inc. (KPTI) Jumps 6.12% on July 15 - Equities.com
07/15/16 08:53 AMKaryopharm Therapeutics Incorporated (NASDAQ:KPTI) Shorted Shares Decreased By 4.69% - Consumer Eagle
07/15/16 08:53 AMKaryopharm Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 08:28 AMAnalyst Target and Average Rating Watch: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Press Telegraph
07/12/16 09:15 AMStock Alert: Alnylam Pharmaceuticals (NASDAQ:ALNY), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), Western ... - KC Register
07/10/16 09:09 AMWere Analysts Bullish Karyopharm Therapeutics Inc (NASDAQ:KPTI) This Week? - Press Telegraph
07/08/16 04:59 PMKaryopharm Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News
07/08/16 04:59 PMBroker Outlook For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Fiscal Standard
07/08/16 04:59 PMIs $20 Within Reach For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Investor Newswire
07/06/16 06:41 AMKaryopharm to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive ...
07/06/16 06:30 AMKaryopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - NEWTON, Mass., July 06, 2016-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer, will present at Cantor ...
07/03/16 04:26 PMHow Many Karyopharm Therapeutics Inc (NASDAQ:KPTI)'s Analysts Are Bullish? - Press Telegraph
07/02/16 07:45 AMIs Karyopharm Therapeutics Inc's Fuel For Real? The Stock Just Increased Again - Engelwood Daily
07/02/16 07:45 AMKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Expected to Reach Highs Of $20 - Investor Newswire
07/02/16 07:45 AMRecently Issued Stock Ratings For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Fiscal Standard
06/28/16 09:45 AMKaryopharm Therapeutics (NASDAQ:KPTI) target price bumped up to $16 as covered today by Robert W. Baird
06/25/16 08:41 AMStrong Sell Calls Recommendations For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 0 - Investor Newswire
06/23/16 05:16 PMKaryopharm Therapeutics : Initiates Phase 1 Clinical Trial with KPT-9274
06/23/16 05:16 PMKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL
06/22/16 09:31 AMKaryopharm Therapeutics (KPTI) Commences KPT-9274 Phase 1 in Adv. Solid Malignancies or NHL - StreetInsider.com
06/22/16 09:26 AMKaryopharm Commences First Stage Clinical Study With KPT-9274 -
06/22/16 06:39 AMKaryopharm Initiates Phase 1 Clinical Trial with KPT-9274 - [at noodls] - NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1 clinical trial ...
06/18/16 04:17 PMStrong Buy Calls Count For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) At 3 - Investor Newswire
06/17/16 04:45 PMKaryopharm Therapeutics : Outlines Key Selinexor Clinical Development Achievements
06/17/16 03:08 PMKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 07:39 AMKaryopharm Outlines Key Selinexor Clinical Development Achievements - [at noodls] - - Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma - - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and Immunotherapeutic ...
06/15/16 06:49 AMKaryopharm to Present at the 2016 JMP Securities Life Science Conference - [at noodls] - NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive ...
06/13/16 07:30 AMKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : June 13, 2016 -
06/10/16 05:04 PMCompany Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Presents Preliminary STOMP Phase 1b Clinical Data ... - Smarter Analyst
06/10/16 07:43 AMKaryopharm Therapeutics (KPTI) Announces Poster Presentation of Updated KPT-330 Phase 1b Data - StreetInsider.com
06/10/16 06:39 AMKaryopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting - [at noodls] - - Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma - - Preclinical Data for Second-Generation ...
06/08/16 05:11 PMKARYOPHARM THERAPEUTICS INC. (NASDAQ:KPTI) Financial Condition Compared to S&P 500 - CML News
06/08/16 07:40 AMKaryopharm Therapeutics Inc. (KPTI) is Trading Higher on Unusual Volume for June 06 - Equities.com
06/07/16 07:27 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 17,855 shares
06/06/16 08:36 AMRaymond James Initiates Coverage on Karyopharm Therapeutics Inc to Outperform - Trade Calls
06/04/16 07:40 AMChione Ltd, 10% Owner of Karyopharm Therapeutics Inc (NASDAQ:KPTI) sells 40,000 shares
06/02/16 05:09 PMKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Update & Estimates - Stock Tick Tock - Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to post earnings of $-0.75 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 07:43 AMKaryopharm Therapeutics Inc (KPTI) Lowered to Hold at Jefferies Group - Let Me Know About This - Karyopharm Therapeutics Inc (KPTI) Lowered to Hold at Jefferies GroupLet Me Know About ThisKaryopharm Therapeutics logo Karyopharm Therapeutics Inc (NASDAQ:KPTI) was downgraded by equities researchers at Jefferies Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, ...A Major Shareholder at Karyopharm Therapeutics (NASDAQ: KPTI) is Selling SharesAnalyst Ratingsall 4 news articles »
06/01/16 07:40 AMKaryopharm Therapeutics Inc (KPTI) is Trading Higher on Unusual Volume for May 30 - Equities.com - Karyopharm Therapeutics Inc (KPTI) is Trading Higher on Unusual Volume for May 30Equities.comKaryopharm Therapeutics Inc (KPTI) experienced unusually high volume on May. 30, as the stock gained 0.94% to a closing price of $9.62. The stock saw 333,672 shares trade hands over the course of the day on 2,198 trades. Given that the stock's average ...and more »
06/01/16 07:03 AMKaryopharm to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, ...
05/31/16 05:03 PMNews Sentiment For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Investor Newswire - News Sentiment For Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Investor NewswireKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Average broker stands at 2 while it was 2 three months ago. The quarterly report of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) can be made public close to 2016-08-08. It is estimated by the recent update ...and more »
05/31/16 09:05 AMStock Review and Earnings Check on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - HNN - Stock Review and Earnings Check on Karyopharm Therapeutics Inc. (NASDAQ:KPTI)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report quarterly EPS of $-0.71. The company's next earnings report is expected to be ...and more »
05/27/16 07:34 PMRaymond James Initiates Coverage on Karyopharm Therapeutics Inc. (KPTI) By Announcing An Initial Rating Of “Outperform” - Karyopharm Therapeutics Inc. (NASDAQ:KPTI). On March 15 Jefferies maintained a company rating of “Hold” and lowered the price expectation to $10.00 from $14.00. Equity analyst Bank of America downgraded the stock and lowered the price target on March ...
05/27/16 07:21 AMCoverage initiated on Karyopharm Therapeutics by Raymond James -

Social

About Karyopharm Therapeutics

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KPTI
  • CUSIP:
Key Metrics:
  • Previous Close: $7.03
  • 50 Day Moving Average: $7.70
  • 200 Day Moving Average: $7.90
  • P/E Ratio: N/A
  • P/E Growth: 0.17
  • Market Cap: $256.39M
  • Beta: 4.36
  • Current Year EPS Consensus Estimate: $-3.09 EPS
  • Next Year EPS Consensus Estimate: $-2.94 EPS
Additional Links:
Karyopharm Therapeutics (NASDAQ:KPTI) Chart for Monday, July, 25, 2016